Our first approved homegrown recombinant mAb highlights our unwavering dedication to advancing care for those with HAE – a community we have supported for over 40 years. We are committed to improving the lives of patients around the world. Read more:

We are proud to announce that Australia’s TGA has approved the first and only once-monthly treatment targeting factor XIIa to prevent attacks of #HAE. Read more:

🎉✨ Cheers to a fresh start and endless possibilities! As we welcome 2025, let’s embrace new adventures, chase big dreams, and celebrate every moment along the way. Here’s to health, happiness, and success for all in the year ahead. 🥂🎆 #HappyNewYear #CSL

🎄✨ This holiday season, we’re filled with gratitude for the moments, memories, and people that make life so special. May your days be merry, your hearts full, and your home warm with love. Wishing you a joyful Christmas! ❤��🎁 #MerryChristmas #CSL

We recently received a positive CHMP opinion for our monoclonal antibody targeting factor Xlla to prevent #HAE attacks. We’re proud to continue serving the HAE community and driving innovation forward.

We are proud to announce we have received a positive CHMP opinion for our once-monthly treatment targeting factor Xlla for #HAE. Read more:

@flucoalition For facts about flu vaccines, flu season updates and tips/prevention methods, we recommend visiting To stay up-to-date on vaccine guidance and influenza news, the CDC’s website is also an excellent resource. #FluChat

@flucoalition .@AIMimmunization is once again showing up this flu season as a national voice and forum for immunization program leaders to collaborate, share information and promote policies to help reduce vaccine-preventable diseases. Outstanding work! #FluChat

@flucoalition While eligible people six months and older should get a flu vaccination by the end of October, the CDC states that vaccination will still be beneficial and provide protection as long as influenza viruses are circulating. #FluChat

There is no evidence of the ability of H5N1 avian influenza virus currently circulating to cause human to human transmission. However, the CDC and other health agencies worldwide are closely monitoring the situation due to the pandemic potential of avian influenza viruses. Effective pandemic preparedness necessitates a collaborative effort globally, underpinned by a network of manufacturing, distribution, strong immunization programs and robust global surveillance. As a global leader in outbreak and pandemic influenza preparedness, CSL Seqirus has extensive preparedness plans and activities with over 30 governments. #FluChat

@flucoalition Several factors may account for this decline, including vaccine fatigue and misunderstandings about the importance of vaccination. By supporting healthcare professionals and working with agencies like the CDC, we can help restore vaccination rates to pre-pandemic levels. #FluChat

At CSL Seqirus, we are committed to protecting public health by collaborating with various stakeholders to foster a healthier future. Our broad portfolio of influenza vaccines plays a critical role in safeguarding communities worldwide. Influenza remains a significant threat, contributing to nearly half of all hospitalizations due to infectious diseases during the 2023/24 flu season. This highlights the importance of annual influenza vaccination for all eligible individuals as a vital measure to prevent influenza and its complications. #FluChat

Applications for the #CSLBehring #ProfHeimburgerAward2025 are now extended to November 18, 2024; 11:59pm CET! Visit to apply. Applications are subject to eligibility #earlycareerresearchers #hematology #inheritedbleedingdisorders #acquiredbleedingdisorders

Congratulations to @qizhang85 from @SAiGENCI, @UniofAdelaide who was tonight awarded a 2025 CSL Centenary Fellowship. She is investigating the fundamental processes by which our cells turn genes on and off as they change identities.

Congratulations to @DrClareWeeden from @WEHI_research who was tonight awarded a 2025 CSL Centenary Fellowship for her research on the cellular changes that can lead to lung cancer, and on ways to detect, stop and even reverse those changes.

CSL is proud to have been recognised as 'Manufacturer of the Year - Large Business' and 'Leader in Health Technologies' at the Victorian Manufacturing Hall of Fame Awards 2024. Congratulations to our teams for all their hard work!

As #SickleCellAwarenessMonth comes to an end, we remain committed to helping those with sickle cell better manage their disease through ongoing research and solutions. Read more here:

CSL was honored to have received recognition at the recent @FundSickleCell conference, where our work in sickle cell research was awarded as one of the top three abstracts. We are dedicated to advancing science and delivering hope to patients.

Applications for the #ProfHeimburgerAward2025 cycle are open! Five #earlycareerresearchers will receive a grant to support their research in inherited or acquired #bleedingdisorders. Applications close November 11:

We are delighted to receive approval in Japan for our updated sa-mRNA COVID-19 vaccine and remain committed to advancing innovative vaccine technology for viral respiratory diseases. Read more here: